117 related articles for article (PubMed ID: 33905529)
1. Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries.
Gogebakan KC; Mukherjee K; Berry EG; Sonmez K; Leachman SA; Etzioni R
Cancer; 2021 Aug; 127(16):2926-2933. PubMed ID: 33905529
[TBL] [Abstract][Full Text] [Related]
2. Direct economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked database.
Davis KL; Mitra D; Kotapati S; Ibrahim R; Wolchok JD
Appl Health Econ Health Policy; 2009; 7(1):31-41. PubMed ID: 19558193
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data.
Seidler AM; Pennie ML; Veledar E; Culler SD; Chen SC
Arch Dermatol; 2010 Mar; 146(3):249-56. PubMed ID: 20231494
[TBL] [Abstract][Full Text] [Related]
4. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
[TBL] [Abstract][Full Text] [Related]
5. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
[TBL] [Abstract][Full Text] [Related]
6. Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for Melanoma.
Bateni SB; Nguyen P; Eskander A; Seung SJ; Mittmann N; Jalink M; Gupta A; Chan KKW; Look Hong NJ; Hanna TP
JAMA Dermatol; 2023 Nov; 159(11):1195-1204. PubMed ID: 37672282
[TBL] [Abstract][Full Text] [Related]
7. Nonoperative care to manage sacroiliac joint disruption and degenerative sacroiliitis: high costs and medical resource utilization in the United States Medicare population.
Ackerman SJ; Polly DW; Knight T; Holt T; Cummings J
J Neurosurg Spine; 2014 Apr; 20(4):354-63. PubMed ID: 24527824
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of renal cell carcinoma among older adults in the targeted therapy era.
Kale HP; Mays DP; Nadpara PA; Slattum PW; Paul AK; Carroll NV
Urol Oncol; 2019 Jun; 37(6):356.e19-356.e28. PubMed ID: 30846388
[TBL] [Abstract][Full Text] [Related]
9. An estimate of the annual direct cost of treating cutaneous melanoma.
Tsao H; Rogers GS; Sober AJ
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):669-80. PubMed ID: 9591809
[TBL] [Abstract][Full Text] [Related]
10. Cost of cancer management by stage at diagnosis among Medicare beneficiaries.
Reddy SR; Broder MS; Chang E; Paydar C; Chung KC; Kansal AR
Curr Med Res Opin; 2022 Aug; 38(8):1285-1294. PubMed ID: 35285354
[TBL] [Abstract][Full Text] [Related]
11. Esophageal cancer treatment costs by phase of care and treatment modality, 2000-2013.
Tramontano AC; Chen Y; Watson TR; Eckel A; Hur C; Kong CY
Cancer Med; 2019 Sep; 8(11):5158-5172. PubMed ID: 31347306
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare.
Sheehan DF; Criss SD; Chen Y; Eckel A; Palazzo L; Tramontano AC; Hur C; Cipriano LE; Kong CY
Cancer Med; 2019 Jan; 8(1):94-103. PubMed ID: 30575329
[TBL] [Abstract][Full Text] [Related]
13. Costs and trends in pancreatic cancer treatment.
O'Neill CB; Atoria CL; O'Reilly EM; LaFemina J; Henman MC; Elkin EB
Cancer; 2012 Oct; 118(20):5132-9. PubMed ID: 22415469
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003.
Cipriano LE; Romanus D; Earle CC; Neville BA; Halpern EF; Gazelle GS; McMahon PM
Value Health; 2011 Jan; 14(1):41-52. PubMed ID: 21211485
[TBL] [Abstract][Full Text] [Related]
15. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.
Riley GF; Potosky AL; Lubitz JD; Kessler LG
Med Care; 1995 Aug; 33(8):828-41. PubMed ID: 7637404
[TBL] [Abstract][Full Text] [Related]
16. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
17. Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data.
Lang K; Huang H; Sasane M; Paly VF; Hao Y; Menzin J
BMC Health Serv Res; 2014 Jul; 14():298. PubMed ID: 25008431
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.
Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A
Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407
[TBL] [Abstract][Full Text] [Related]
19. The Cost of Metastatic Prostate Cancer in the United States.
Olsen TA; Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2023 Jan; 10(1):41-47. PubMed ID: 37103444
[TBL] [Abstract][Full Text] [Related]
20. Medical Care Costs Associated With Cancer in Integrated Delivery Systems.
Banegas MP; Yabroff KR; O'Keeffe-Rosetti MC; Ritzwoller DP; Fishman PA; Salloum RG; Lafata JE; Hornbrook MC
J Natl Compr Canc Netw; 2018 Apr; 16(4):402-410. PubMed ID: 29632060
[No Abstract] [Full Text] [Related]
[Next] [New Search]
